Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells

Clinical and Experimental Metastasis

Volumn 24, Issue 1, 2007, Pages 57-66

  Elstner, Anja ^a   Holtkamp, Nikola ^a   Von Deimling, Andreas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

DFO; Glioblastoma; Hif 1; Invasion; Iron

Indexed keywords

DEFEROXAMINE; FERRIC AMMONIUM CITRATE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1; IRON; IRON CHELATING AGENT; UROKINASE RECEPTOR;

ARTICLE; CELL INVASION; CELL LEVEL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HUMAN CELL; IRON CELL LEVEL; IRON DEPLETION; PHENOTYPE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; DEFEROXAMINE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; IRON CHELATING AGENTS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34147119131     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9057-y     Document Type: Article

References (45)

1. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N (2005) Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 238(2):188-196
2. Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY (1990) Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol 68:1364-1371
3. Renton FJ, Jeitner TM (1996) Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol 51:1553-1561
4. Buss JL, Greene BT, Turner J, Torti FM, Torti SV (2004) Iron chelators in cancer chemotherapy. Curr Top Med Chem 4:1623-1635
5. Yuan J, Lovejoy DB, Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458
6. Becton DL, Bryles P (1988) Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48:7189-7192
7. Donfrancesco A, Deb G, Dominici C, De Sio L, Inserra A, Boglino C, Takahashi M, Uchino J, Helson L (1995) D-CECaT as preoperative chemotherapy for unresectable neuroblastoma in children over one year of age. Anticancer Res 15:2347-2350
8. Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, Gelfand EW, Freedman MH (1987) In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69:757-761
9. Ye Z, Connor JR (1999) Screening of transcriptionally regulated genes following iron chelation in human astrocytoma cells. Biochem Biophys Res Commun 264:709-713
10. Dayani PN, Bishop MC, Black K, Zeltzer PM (2004) Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 67:367-377
11. Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR (2002) Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci 115:2165-2177
12. Recht L, Torres CO, Smith TW, Raso V, Griffin TW (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72:941-945
13. Holtkamp N, Afanasieva A, Elstner A, van Landeghem FK, Konneker M, Kuhn SA, Kettenmann H, von Deimling A (2005) Brain slice invasion model reveals genes differentially regulated in glioma invasion. Biochem Biophys Res Commun 336:1227-1233
14. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624-1636
15. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME (2001) Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 53:161-176
16. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628
17. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, Weller M (2000) Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 19:4210-4220
18. Wang GL, Semenza GL (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82:3610-3615
19. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835
20. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, Newcomb EW (2003) Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196:394-402
21. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8:2714-2724
22. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887
23. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331:370-375
24. Nozaki S, Endo Y, Nakahara H, Yoshizawa K, Hashiba Y, Kawashiri S, Tanaka A, Nakagawa K, Matsuoka Y, Kogo M, Yamamoto E (2005) Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 41:971-977
25. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845-6848
26. Mialon A, Sankinen M, Soderstrom H, Junttila TT, Holmstrom T, Koivusalo R, Papageorgiou AC, Johnson RS, Hietanen S, Elenius K, Westermarck J (2005) DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol 25:5040-5051
27. Ameri K, Lewis CE, Raida M, Sowter H, Hai T, Harris AL (2004) Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 103:1876-1882
28. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63:1138-1143
29. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618
30. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65:7259-7266
31. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920-927
32. 2-regulated prolyl hydroxylation. Science 292:468-472
33. Kunishio K, Okada M, Matsumoto Y, Nagao S (2003) Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 20:39-45
34. Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP (2006) Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25:2379-2392
35. Furukawa K, Kumon Y, Harada H, Kohno S, Nagato S, Teraoka M, Fujiwara S, Nakagawa K, Hamada K, Ohnishi T (2006) PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules. Int J Oncol 29:73-81
36. Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML, Kohn EC (1997) Inhibitory effects of CAI in glioblastoma growth and invasion. J Neurooncol 32:93-101
37. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS (2004) RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23:8486-8496
38. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS (2005) Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4:1399-1408
39. Mori T, Abe T, Wakabayashi Y, Hikawa T, Matsuo K, Yamada Y, Kuwano M, Hori S (2000) Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J Neurooncol 46:115-123
40. Tan X, Egami H, Nozawa F, Abe M, Baba H (2006) Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. Int J Oncol 28:369-374
41. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S (1999) Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80:617-623
42. Richardson DR, Ponka P (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306-315
43. Beerepoot LV, Shima DT, Kuroki M, Yeo KT, Voest EE (1996) Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res 56:3747-3751
44. Hoffbrand AV, Wonke B (1989) Results of long-term subcutaneous desferrioxamine therapy. Baillieres Clin Haematol 2:345-362
45. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 107(9): 3455-3462